Neuraxpharm enters booming CBD market with the acquisition of leading Switzerland-based S.T.U GMBH
-Neuraxpharm establishes Swiss footprint with acquisition of leading cannabidiol company
-S.T.U. GmbH is the owner of market leading brand Hemplix™
October 29, 2019
Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the central nervous system (CNS), announces today the acquisition of S.T.U. GmbH (Swiss Trade Union or S.T.U.), a leading Switzerland-based developer and distributor of natural cannabidiol (CBD) consumer products.
The deal enables Neuraxpharm to enter the fast-growing CBD space and to build on its business of CNS-related products, including value added medicines, standard generics and consumer healthcare products. The acquisition is in line with Neuraxpharm’s strategy to expand its presence in Europe entering a key market. Switzerland is now the 10th European market where Neuraxpharm will have a direct presence. It is the fifth country the company has extended its footprint in 2019.
